Malignant Melanoma
📧 Sign up to get email alerts when something new happens for Malignant Melanoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-03-20Clinical Trial Update: A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies [Phase 1]
This Phase 1 trial evaluates the pharmacokinetic interaction between vemurafenib and a single dose of tizanidine in patients with BRAFV600 m…
-
CLINICAL_TRIALS trial_result · 2017-03-01Clinical Trial Update: Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer [Phase 2]
A Phase 2 trial evaluating recombinant interleukin-21 (rIL-21) for metastases in lymph nodes due to malignant melanoma. The study has been t…
-
CLINICAL_TRIALS other · 2017-02-24Clinical Trial Update: Bevacizumab vs Dacarbazine in Metastatic Melanoma [Phase 2]
A Phase 2 trial comparing bevacizumab versus dacarbazine in metastatic unresectable malignant melanoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma [NA]
Completed Phase I trial evaluating intratumoral delivery of an interleukin-12 plasmid (pIL-12) by electroporation in malignant melanoma.
-
CLINICAL_TRIALS withdrawal · 2017-02-08Clinical Trial Update: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
The expanded access program for nivolumab in combination with ipilimumab in patients with unresectable or metastatic malignant melanoma is n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) [Phase 1]
This Phase 1 pharmacokinetics study evaluated the effect of rifampin on the pharmacokinetics of vemurafenib (Zelboraf) in patients with mali…
-
CLINICAL_TRIALS trial_result · 2016-12-15Clinical Trial Update: Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System [Phase 2]
This Phase 2 clinical trial evaluating temozolomide with radiation therapy for stage IV malignant melanoma with measurable and unresectable …
-
CLINICAL_TRIALS trial_result · 2016-11-17Clinical Trial Update: A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies [Phase 2, Phase 3]
This clinical trial update reports results from a study of continued treatment with peginterferon alfa-2a or recombinant interferon alfa-2a …
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma [Phase 1]
Genentech completed a Phase 1 study of the investigational agent DEDN6526A in patients with metastatic or unresectable malignant melanoma. T…
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy [Phase 1]
A completed Phase 1 trial evaluating the effect of vemurafenib on the pharmacokinetics of phenprocoumon in patients with BRAFV600 mutation-p…
-
CLINICAL_TRIALS trial_result · 2016-11-02Clinical Trial Update: A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy [Phase 1]
This Phase 1 trial evaluated the pharmacokinetic interaction between vemurafenib and acenocoumarol in BRAFV600 mutation-positive metastatic …
-
CLINICAL_TRIALS research · 2016-10-25Clinical Trial Update: Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma
This update describes a study aimed at defining an immune signature that predicts response to anti-PD-1 antibodies in advanced melanoma. The…
-
CLINICAL_TRIALS trial_result · 2016-09-29Clinical Trial Update: Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) [Phase 1, Phase 2]
Clinical trial update on Phase I/II study of ipilimumab (MDX-010) in unresectable stage III or IV malignant melanoma, focusing on predictive…
-
CLINICAL_TRIALS trial_result · 2016-09-28Clinical Trial Update: A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide [Phase 2]
A Phase 2 study evaluating the CTLA-4 antibody MDX-010 (BMS-734016) with or without prophylactic oral budesonide in patients with malignant …
-
CLINICAL_TRIALS trial_result · 2016-08-15Clinical Trial Update: Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma [Phase 1, Phase 2]
An early-stage study evaluated an mRNA-transfected dendritic cell vaccine in patients with advanced malignant melanoma. The Phase 1/2 trial …
-
CLINICAL_TRIALS trial_result · 2016-06-17Clinical Trial Update: A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma [Phase 1]
Phase 1 study evaluating vemurafenib with cobimetinib (GDC-0973) in BRAFV600E mutation-positive metastatic melanoma completed with posted re…
-
CLINICAL_TRIALS trial_result · 2016-06-09Clinical Trial Update: Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma [Phase 1]
A Phase 1 study evaluating radiotherapy in combination with ipilimumab for unresectable stage III or stage IV malignant melanoma has been te…
-
CLINICAL_TRIALS trial_result · 2016-06-08Clinical Trial Update: An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma [Phase 1]
Phase 1 trial update evaluating the combination of bortezomib and sorafenib in advanced malignant melanoma has completed.
-
CLINICAL_TRIALS trial_result · 2016-06-08Clinical Trial Update: A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma [Phase 1]
A Phase 1 trial update of vemurafenib in Chinese participants with BRAF V600 mutation-positive unresectable or metastatic melanoma has compl…
-
CLINICAL_TRIALS research · 2016-06-07Clinical Trial Update: In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma [Phase 1, Phase 2]
This clinical trial registry entry describes an IHNI-based boron neutron capture therapy approach being studied for malignant melanoma in Ph…
-
FDA approval · 2016-04-27FDA Approved: TEMOZOLOMIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for temozolomide in a generic form, enabling Rising Pharma Holdings, Inc. to market temozolomide.
-
CLINICAL_TRIALS trial_result · 2016-03-02Clinical Trial Update: FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 2]
Phase 2 clinical trial update for FR901228 in unresectable stage III or stage IV malignant melanoma (melanoma) has been terminated with resu…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors [Phase 1, Phase 2]
This clinical trial update summarizes the completed Phase I/IIa study of AdCD40L immunogene therapy for malignant melanoma (and other solid …
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: A Study of RO5185426 in Patients With Metastatic Melanoma [Phase 2]
Phase 2 study of RO5185426 in metastatic melanoma has completed, with results posted in 2016.
-
CLINICAL_TRIALS trial_result · 2016-02-08Clinical Trial Update: Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma [Phase 2]
Phase 2 trial comparing nivolumab plus ipilimumab versus ipilimumab alone in previously untreated unresectable or metastatic melanoma has co…